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Background: European data, at least from Western Europe, are relatively good on migraine prevalence but less
sound for tension-type headache (TTH) and medication-overuse headache (MOH). Evidence on impact of headache
disorders is very limited. Eurolight was a data-gathering exercise primarily to inform health policy in the European
Union (EU). This manuscript reports personal impact.
Methods: The study was cross-sectional with modified cluster sampling. Surveys were conducted by structured
questionnaire, including diagnostic questions based on ICHD-II and various measures of impact, and are reported
from Austria, France, Germany, Italy, Lithuania, Luxembourg, Netherlands, Spain and United Kingdom. Different
methods of sampling were used in each. The full methodology is described elsewhere.
Results: Questionnaires were analysed from 8,271 participants (58% female, mean age 43.4 y). Participation-rates,
where calculable, varied from 10.6% to 58.8%. Moderate interest-bias was detected. Unadjusted lifetime prevalence
of any headache was 91.3%. Gender-adjusted 1-year prevalences were: any headache 78.6%; migraine 35.3%; TTH
38.2%, headache on ≥15 d/mo 7.2%; probable MOH 3.1%. Personal impact was high, and included ictal symptom
burden, interictal burden, cumulative burden and impact on others (partners and children). There was a general
gradient of probable MOH >migraine > TTH, and most measures indicated higher impact among females. Lost
useful time was substantial: 17.7% of males and 28.0% of females with migraine lost >10% of days; 44.7% of males
and 53.7% of females with probable MOH lost >20%.
Conclusions: The common headache disorders have very high personal impact in the EU, with important
implications for health policy.
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The World Health Report 2001, published by the World
Health Organization (WHO), ranked migraine 19th
among the causes of disability worldwide, responsible
for 1.4% of all years of life lost to disability (YLDs) [1].
Although this finding has been cited repeatedly, it
considerably underreported the disability that migraine
imposes on people throughout the world. The reason* Correspondence: t.steiner@imperial.ac.uk
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in any medium, provided the original work is pwas lack of good evidence. In the Global Burden of
Disease Survey 2000 (GBD2000), on which the World
Health Report 2001 was based, estimates for migraine
were derived from very scarce data for China, India and
most other countries in South East Asia, most of Africa,
all of the Eastern Mediterranean and all of eastern
Europe – countries in which more than half the world’s
population live. Moreover, GBD2000 gave no account of
headache disorders other than migraine: tension-type
headache (TTH) and medication-overuse headache (MOH)
did not feature, despite contributing significantly to the
global disability burden of disease [2]. For these dis-
orders, at that time, dependable evidence was lacking
everywhere.n Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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Global Campaign against Headache [3-11]. In conse-
quence, the Global Burden of Disease Survey 2010
(GBD2010) [12] was much better informed. In this
survey, TTH and migraine, with estimated global preva-
lences of 20.1% and 14.7% respectively, ranked as second
and third most common diseases in the world (behind
dental caries) in both males and females. Migraine was
recognized as the seventh highest among specific causes
of disability globally, responsible for 2.9% of all YLDs
[12-15].
There are many uncertainties surrounding surveys
such as GBD and the rankings they derive as products of
prevalence and disability weights. GBD2010 was a much
better account of the global burden of headache than
GBD2000, but still incomplete [13-15]. It failed to ac-
knowledge the interictal impairments associated with
migraine. It altogether ignored MOH. This disorder,
which might be regarded as a complication of either mi-
graine or TTH (and should therefore be included in the
reckoning of both), undoubtedly causes substantial disabil-
ity. Nevertheless, GBD2010 confirmed the widespread
opinion both among members of the lay headache organi-
zations of Europe and among headache specialists that
headache disorders receive far less attention than they de-
serve as major causes of public ill-health [16], a view very
clearly supported by WHO [7].
As far as Europe is concerned, good data exist on mi-
graine prevalence derived from a number of western
countries [17,18]. Data are less good for TTH and
MOH. With regard to impact of headache disorders, evi-
dence is quite limited for migraine [16] and non-existent
for TTH and MOH. The Eurolight project, supported by
the EC European Agency for Health and Consumers of
the European Commission, was a data-gathering exercise
undertaken primarily to inform health policy on head-
ache disorders in the European Union (EU). This manu-
script reports the principal findings with regard to the
personal impact of headache, which translates into pub-
lic ill-health. Our findings on financial cost and societal
impact are published elsewhere [19].Methods
The study was of cross-sectional design and used modi-
fied cluster sampling. There was pragmatic regard to
convenience in the selection of countries, and areas
within those countries, from which samples were drawn.
Using the same questionnaire, translated into the local
languages, surveys were conducted in 10 countries:
Austria, France, Germany, Ireland, Italy, Lithuania,
Luxembourg, Netherlands, Spain and United Kingdom
(UK). The full methodology is described elsewhere [20];
below we present brief details.Project organization
The Eurolight project was a collaboration of 25 groups
from 15 different countries: two public bodies (CRP
Santé, Luxembourg, and Regione Lombardia—Sanità, Italy);
clinicians from 11 hospitals; the professional European
Headache Federation (EHF); nine European patients’ or-
ganizations including the European Headache Alliance
(EHA); the World Headache Alliance (WHA); and Lifting
The Burden (LTB), a UK-registered nongovernmental
organization directing the Global Campaign against
Headache in official relations with WHO.
Ethics
The National Ethics Committee of Luxembourg gave over-
all approval of the protocol. Further approvals were
obtained from national or local ethics committees wher-
ever needed as the methods for recruitment of participants
differed between countries. Similarly, data protection ap-
provals were obtained centrally in Luxembourg and at
country levels in compliance with national and European
privacy laws.
In each country, prospective participants received a
written information sheet explaining the project and
enquiry, and their purpose.
Questionnaire
The development, content and validation of the struc-
tured questionnaire have been previously described [21].
The original English version was translated into Dutch,
French, German, Italian, Lithuanian, Luxembourgish,
Portuguese and Spanish according to LTB’s standardized
translation protocol for lay documents [22].
Demographic questions were followed by neutral
screening questions for headache (“Have you ever had a
headache?” and “Have you had a headache during the
last year?”) and, in those screening positively, by
headache-diagnostic questions and several question sets
addressing impact.
Diagnosis
The diagnostic questions were imported, with linguistic
adaptations as necessary, from the burden-of-headache
questionnaire developed by LTB for population-based
surveys (the HARDSHIP questionnaire [23]). When par-
ticipants reported more than one headache type, ques-
tions were directed to the one identified as the most
bothersome. Diagnoses were made by computerized
algorithm also developed by LTB specifically for this
questionnaire [23]. The algorithm first identified, and
separated, participants reporting headache on ≥15 days/
month (of whom additional questions enquired into
medication use), then to the remainder applied ICHD-
II criteria [24] for migraine, TTH, probable migraine
and probable TTH in that order. Thus a diagnosis of
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migraine and probable migraine were considered together,
as were TTH and probable TTH [25,26]. Probable MOH
was assumed to be the diagnosis when headache frequency
was ≥15 d/mo, duration was >4 h, the question “Do you
usually take medication to treat your headaches” was an-
swered “yes”, and frequency of acute medication use was
≥15 d/mo if the medication was simple analgesics only
and ≥10 d/mo if any other (compound analgesics, opioids,
triptans and/or ergots). A diagnosis of probable MOH
trumped all other diagnoses.
The questionnaire did not attempt to diagnose rela-
tively rare headache disorders such as the trigeminal
autonomic cephalalgias; even in very large samples, no
more than a very few cases would occur.
Sampling and data collection
We adopted sampling methods which varied between
countries according to what was feasible. Again, these
are fully described elsewhere [20]. The sample drawn
from Lithuania was population-based, but those in other
countries were to varying degrees less so (Table 1).
Additional surveys in Spain and the Netherlands, and the
only survey in Ireland, were performed among members of
the national headache patients’ organizations. The samplesTable 1 Summary of data collection methods in each country
organizations
Country* Sample size (n) Methods
Lithuania 1,137 Sample drawn from inhabitants of Kaunas
(in range 18–65 y) and gender compositio
Data collection face-to-face, conducted by
Luxembourg 6,498 Sample aged 18–65 y, stratified for age, ge
social security registry (IGSS). Questionnair
non-responders.
Spain 1,700 Random sample of employees of various c
stratified to be representative of general w
and education. Ten occupational health p
by telephone to non-responders.
Germany 3,000 Random urban (50%) and rural (50%) sam
municipal authority. Questionnaires distrib
Italy 3,500 Random urban (70%) and rural (30%) sam
Sanitaria Locale of Pavia, stratified with reg
distributed and returned by post. No remi
France 2,400 Consecutive patients aged 18–65 y attend
pre-specified day. Questionnaires to be co
by email after one week to non-responde
Austria up to 6,000 Up to 10 consecutive patients aged 18–65
pre-specified day. Questionnaires to be co
responders.
Netherlands unknown Survey conducted by TNS-NIPO, a market r
representative with regard to gender, age (
internet, to be completed on-line. Study sto
UK 720 Modified population-based sampling attem
are registered with local GP). Questionnair
over a period of time, to be completed an
*Listed in descending order corresponding to how well the sample was populationgenerated from these were inevitably biased, and the data
from them are not reported here.Non-responder study
Participation rates were low in some countries and we
recognized that questionnaires were more likely to be
completed and returned by those most affected by head-
ache (a form of participation bias referred to as interest
bias [26]. Therefore, studies of non-responders were per-
formed in Luxembourg, Italy, Netherlands and Germany.
In Italy, non-responders were invited by means of adver-
tisements in local newspapers to complete a short ques-
tionnaire on the website of Centro Italiano di Ricerche
Neurologiche Applicate (CIRNA) (www.cefalea.it). In the
other countries, non-responders were selected randomly
and called by telephone. All were asked whether head-
ache had occurred ever and, if so, during the preceding
year and how often.Data management and analysis
All completed questionnaires were transferred electroni-
cally to the data-management centre at CRP-Santé.
Double-data-entry and reconciliation of inconsistencies
were employed as quality-control procedures., excluding samples drawn through patients’
city and Kaunas region using Residents’ Register Service, reflecting age
n of Lithuania and proportions living in rural (33%) or urban (67%) areas.
medical students “cold-calling” door-to-door.
nder, region and nationality, drawn from general population via national
es distributed and returned by post. Reminders sent one month later to
ompanies operating in national postal services in 10 areas of Spain,
orking population with regard to gender, age (within range 18–65 y)
hysicians delivered and took return of questionnaires. One reminder
ples aged 18–65 y from general population listings supplied by local
uted and returned by post. No reminders sent.
ples drawn from general population using listings supplied by Azienda
ard to gender, age (in range 18–65 y) and education. Questionnaires
nders sent.
ing any of cooperative of 80 general practitioners (GPs) on a
mpleted and returned immediately or later by post. One reminder
rs.
y visiting any of 400 GPs and 200 neurologists for any reason on a
mpleted and returned later. One reminder after one month to non-
esearch company with access to a population sample of 200,000,
in range 18–65 y), region and education. Questionnaire distributed by
pped when >2,000 received back.
pted through 12 GP practices in 11 areas (in UK, virtually all residents
e given to consecutive patients aged 18–65 y attending for any reason
d returned immediately, or later by post.
-based.
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tries only, ignoring those samples derived from the
memberships of national patients’ organizations.
Statistical analyses were performed at CRP-Santé using
SAS version 9.2, and the further calculations of results
described in the text were performed by LJS, using Excel
version 14.0.6123.5001. Analyses presented here are es-
sentially descriptive. The study was neither designed nor
powered to generate prevalence estimates for individual
countries but, through modified cluster sampling, to
produce estimates for the European Union. Because they
were not taken to be nationally representative, country-
derived data were pooled without weighting according
to country population size.
Results
From these nine countries, 8,271 correctly completed
questionnaires were analysed. Participation-rates were
not calculable in Austria and the Netherlands, where the
denominators were unknown, but elsewhere varied from
10.6% to 58.8% (Table 2). Participants had a moderate
female bias (58%) and mean age of 43.4 y; almost two
thirds (65%) were employed and nearly three quarters
(72%) were married or living with a household partner
(Table 2).
In the non-responder studies there were 1,007 par-
ticipants (Germany 260, Italy 202; Luxembourg 357;
Netherlands 188; 51% female overall). Participation rates
in these studies were generally high (Germany 80%;
Luxembourg 87%; Netherlands 72%), although in Italy the
denominator was unknown.
The samples from six countries (n = 6,624) were
derived from the general population, those from Austria,
France and UK (n = 1,647) were derived from health-
care (but not headache-specific) settings (see Table 1).
Lifetime prevalence of any headache (unadjusted forTable 2 Numbers of participants, participation rates and dem
Country Participants
(n)
Denominator
(N)
Participation rate
(n/N) (%)
Gen
(% fem
Austria† 644 unknown, but
not >6,000
not calculable 70
France† 876 2,400 36.5 68
Germany 318 3,000 10.6 57
Italy 487 3,500 13.9 58
Lithuania 573 1,137 50.4 59
Luxembourg 1,833 6,498 28.2 59
Netherlands 2,414 unknown not calculable 50
Spain 999 1,700 58.8 59
UK† 127 720 17.6 65
Overall 8,271 27.5* 58
†Sample derived from health-care setting (see Table 1). *Excluding Austria and Nethgender or age) was 91.3% in the general population
samples, 91.2% in the health-care samples (91.3% overall;
n = 8,271). Lifetime prevalence by gender (overall) was
87.5% in males and 94.3% in females; in males, life-time
prevalence peaked at 92.8% in the age range 20–30 y,
whereas in females there was a plateau at 96-97% in the
age range 20–50 y. The 1-year prevalence was 79.6%
overall, 71.1% in males (with a peak of 81.3% in the age-
range 30–40 y) and 86.0% in females (peaking at 92.7%
in the age-range 20–30 y). In both genders, 1-year
prevalence declined substantially after age 60 y (48.2% in
males, 61.9% in females).
By comparison, in the non-responder studies the life-
time prevalence of headache was slightly lower at 86%
(95% CI: 83.9-88.1%), but the 1-year prevalence was
considerably lower at 64% (95% CI: 61.0-67.0).
Table 3 shows the unadjusted 1-year prevalences of
specific headache types based on the reported most
bothersome headache. In males, migraine prevalence
peaked at 33.5% in the age range 30–40 y; in females
there was a plateau at 37-40% in the age range 20–60 y.
After age 60 y, prevalence fell dramatically in both gen-
ders (males: 12.2%; females 22.3%). TTH showed limited
variation in both genders between 20 and 60 y, but
peaked between 20 and 30 y (males: 46.6%; females:
41.2%).
Adjustment for age and gender was problematic because
of uncertainties about the demographics of any reference
population. In the European Union, the ratio of males to
females among adults aged 18–65 y is very close to 1.00
[27] on which basis the gender-adjusted 1-year prevalences
were: any headache 78.6%; all migraine 35.3%; all
TTH 38.2%, all headache on ≥15 d/mo 7.2%; probable
MOH 3.1%.
Further analyses of prevalence are not presented because
the emphasis of Eurolight was on impact. Regardingographic characteristics of samples per country
der
ale)
Age (y)
(mean [SD])
Employed or self-
employed (%)
Married or living with
partner (%)
48.8 [16.0] 57 75
50.2 [16.7] 52 80
44.6 [12.5] 70 65
43.4 [12.6] 68 92
40.9 [13.8] 65 67
40.5 [12.7] 67 71
42.6 [13.2] 69 69
42.7 [11.9] 83 69
48.0 [18.3] 54 67
43.4 65 72
erlands.
Table 3 One-year prevalences (unadjusted) of specific headache types in the main sample (n = 8,271)
Diagnosis
Prevalence (% [95% CI])
Overall Male Female
Any headache 79.6 [78.7-80.5] 71.1 [69.6-72.6] 86.0 [85.0-87.0]
All migraine 36.6 [35.6-37.6] 26.9 [25.4-28.4] 43.6 [42.2-45.0]
Definite migraine 22.2 [21.3-23.1] 14.8 [13.6-16.0] 27.7 [26.4-29.0]
Probable migraine 14.3 [13.6-15.1] 12.1 [11.0-13.2] 15.9 [14.9-16.9]
All TTH 37.6 [36.6-38.6] 40.7 [39.1-42.3] 35.7 [34.3-37.1]
Definite TTH 30.8 [29.8-31.8] 33.8 [32.2-35.4] 28.9 [27.6-30.2]
Probable TTH 6.8 [6.3-7.3] 6.9 [6.1-7.7] 6.8 [6.1-7.5]
Headache on ≥15 d/mo 7.6 [7.0-8.2] 4.9 [4.2-5.6] 9.5 [8.7-10.3]
Probable MOH 3.3 [2.9-3.7] 1.8 [1.4-2.2] 4.3 [3.7-4.9]
CI: confidence interval; TTH: tension-type headache; MOH: medication-overuse headache.
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frequency was 4.7 d/mo in males and 6.3 d/mo in females;
16.6% of males and 8.7% of females with headache had in-
frequent episodes (<1 d/mo), while 50.0% of males and
42.8% of females with headache experienced episodes on
1–3 d/mo. Thus, in the remaining one third (33.4%) of
males and one half (48.5%) of females (41.7% overall),
headache was a weekly or more frequent occurrence. In
the non-responder studies by comparison, only 24.7% (158
of 639) with headache in the last year reported this level of
frequency.
Personal impact was assessed in part by a set of seven
questions, responses to which are shown in Table 4. In
most of these questions, migraine was 2–3 times as
likely as TTH to be associated with an adverse response,
and probable MOH much more so (eg, 32.9% for ques-
tion 2; 33.7% to question 3; 49.6% to question 5; 30.0%
to question 7). The clear exception was question 6, an-
swered similarly (adversely by about 10%) by those with
migraine and TTH (and by 21.5% with probable MOH).
Personal impact in terms of lost useful time was mea-
sured by the HALT index [28]. In five questions this
captured, over the preceding 3 mo and attributable toTable 4 Personal impact of headache assessed by seven ques
Question
1. Have your headaches interfered with your education?
2. Do you believe your headaches have made you less successful in your car
3. Have your headaches resulted in reduced earnings?
4. Do you avoid telling people that you have headaches?
5. Do you feel that your employer and work colleagues understand and acce
6. Do you feel that your family and friends understand and accept your head
7. Taking into account everything you do to treat your headaches, do you fe
*“Yes” to questions 1–4; “no” to questions 5 and 6; “rarely” or “never” to question 7
†Of those to whom the question was applicable (ie, having headache and being emheadache: a) workdays lost completely, or with product-
ivity reduced to <50% of expected; b) the same for days
of household work or chores, c) days on which family,
social or leisure activities were lost. Summing the re-
sponses to all five questions provided overall estimates
of individual impact. These data were surprisingly uni-
form across countries (Figure 1). Analysis on this basis
by diagnosis and gender (Table 5) found that impact was
always higher in females regardless of diagnosis. Impact
was higher for those with migraine than for those with
TTH, with substantial proportions of the former (17.7%
of males and 28% of females) losing >10 d in 3 mo
(ie, >10% of available days). For those with probable MOH,
impact was much higher, to the extent that half (44.7% of
males, 53.7% of females) reported the loss of >20 d.
Analysis of HALT by categorization in this way does
not yield intuitive information about the amount of time
actually lost; neither does it distinguish between lost
workdays, lost housework days and lost social days. For
these purposes, days lost were analysed as continuous
data (Table 6).
For migraine, mean lost workdays were about 1 day/
month and mean lost housework days were the same intions
Proportion responding
adversely* (%)
Overall Male Female
9.2 7.9 9.9
eer? 7.7 7.0 8.1
8.4 8.0 8.7
31.4 30.1 32.1
pt your headaches? 36.3† 38.9† 34.9†
aches? 10.8 10.5 10.9
el you are in control of your headaches? 13.5 13.0 13.7
.
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Figure 1 Personal impact of headache assessed by HALT index (days lost in preceding 3 months), by country.
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lost days were generally about 1 day per 3 months, with lost
housework days somewhat higher (1.6) in females. How-
ever, the distributions in these disorders were not normal,
with medians of 0 for both disorders in both genders (and
upper quartiles of 0 for TTH) despite ranges of 0–90 or
higher. For these disorders, a small minority of participants
accounted for a highly disproportionate part of the reported
burden. We identified 158 participants (2.4% of those with
headache) who gave responses of ≥45 days to at least one
of lost work, housework or social days, of whom over one
third (59) had probable MOH. Of the others, 74 had
migraine (2.4% of those with this diagnosis) and 24 had
TTH (0.7% of those with TTH). One had unclassified head-
ache. Table 6 shows much higher levels of lost workdays in
probable MOH according to the means, but still with an
overall median of only 1 day/month. Lost housework days
were higher still, about 23% of all days according to the
means, but with medians reflecting about half of this.Table 5 Personal impact of headache assessed by HALT index
and gender
Diagnosis and gender
0-5 days
Migraine
Males 73.0 [±3.0]
Females 57.7 [±2.3]
Tension-type headache
Males 92.0 [±1.5]
Females 87.5 [±1.7]
Probable medication-overuse headache
Males 34.0 [±13.5]
Females 31.4 [±8.3]
CI: confidence interval.There was a direct enquiry into interictal burden. First,
participants were instructed to think carefully about the
last day when they did not have headache. Then they
were asked three questions specifically about that day:
 “On that day, were you anxious or worried about
your next headache episode?”
 “On that day, was there anything you could not do
or did not do because you wanted to avoid getting a
headache?”
 “On that day, did you feel completely free from all
headache-related symptoms?”.
All were answerable “yes” or “no”, and the analysis in
Table 7 sums the adverse responses (“yes” to the first
two questions, “no” to the third).
Gender differences were small in this analysis, while the
differences between migraine and TTH suggested some-
what – but not markedly – greater interictal burden in the(days lost in preceding 3 months), by diagnosis
Days lost (% [95% CI])
6-10 days 11-20 days >20 days
9.3 [±2.0] 7.8 [±1.8] 9.9 [±2.0]
14.4 [±1.6] 12.2 [±1.5] 15.8 [±1.7]
3.3 [±1.0] 2.2 [±0.8] 2.5 [±0.8]
5.4 [±1.1] 3.4 [±0.9] 3.7 [±1.0]
10.6 [±8.8] 10.6 [±8.8] 44.7 [±14.2]
6.6 [±4.4] 8.3 [±4.9] 53.7 [±8.9]
Table 6 Personal impact of headache assessed as headache-attributed lost work, housework and social days in
preceding 3 months, by diagnosis and gender
Diagnosis and gender
Days lost in preceding 3 months
Workdays Housework days Social days
Mean
[SD]
Range Median Upper
quartile
Mean
[SD]
Range Median Upper
quartile
Mean
[SD]
Range Median Upper
quartile
Migraine 3.2 [8.6] 0-120 0 3 4.6 [9.2] 0-115 1 6 2.1 [5.0] 0-90 0 2
Males 2.9 [9.4] 0-120 0 2 3.3 [8.7] 0-100 0 2 1.7 [4.8] 0-90 0 2
Females 3.4 [8.3] 0-90 0 3 5.2 [9.4] 0-115 2 6 2.3 [5.1] 0-90 0 3
Tension-type headache 1.0 [5.7] 0-90 0 0 1.3 [5.7] 0-90 0 0 0.6 [3.9] 0-90 0 0
Males 1.0 [6.0] 0-90 0 0 1.0 [5.5] 0-90 0 0 0.6 [3.9] 0-90 0 0
Females 1.0 [5.5] 0-90 0 0 1.6 [5.8] 0-90 0 1 0.7 [3.8] 0-86 0 0
Probable MOH 14.2 [26.1] 0-180 3 17 21.4 [26.7] 0-155 12 30 9.0 [16.2] 0-90 3 10
Males 15.1 [32.7] 0-180 2 10 20.0 [31.5] 0-150 6 24 9.7 [18.6] 0-90 2 10
Females 13.9 [23.3] 0-155 5 20 21.9 [25.3] 0-155 14 30 8.8 [15.3] 0-90 3 10
MOH: medication-overuse headache; SD: standard deviation.
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revealed surprisingly little effect; for example, among
participants with migraine headache on 10–14 d/mo,
15.5% recorded no adverse responses, 61.6% gave one,
18.6% gave two and only 4.3% answered adversely
to all questions. These findings were very similar to
those for probable MOH, occurring by definition
on ≥15 d/mo.
Seven questions enquired into impact on others, in
three areas of family life (Table 8). In these there were
some gender effects. For question 1, females with mi-
graine answered “yes” four times as often as males, and
females with probable MOH three times as often as
males. Females with migraine answered “yes” to question
5 about twice as often as males. In this and all other
questions except 4, males with probable MOH answered
“yes” rather more often (up to 1.5 times) than females.
In most cases, likelihood of responding “yes” wasTable 7 Interictal burden assessed by three questions
Diagnosis and gender
0
Migraine
Males 17.3
Females 15.1
Tension-type headache
Males 18.7
Females 14.9
Probable medication-overuse headache
Males 15.0
Females 18.2strongly correlated with reported headache frequency,
although numbers were small for some of these analyses.
Discussion
This was a very large and organizationally complex study,
involving multiple collaborating partners (academic and
lay) in ten countries. We made pragmatic methodological
compromises in order to complete it.
A considerable strength of the study was the use
everywhere of the same instrument (questionnaire). Not
only that, but the questionnaire was derived from the
HARDSHIP questionnaire, already used by LTB in many
different countries, cultures and translations [23]. The
very neutral screening questions are expected to have
led to better ascertainment, and therefore higher head-
ache prevalence estimates, than questions requiring a
certain degree or frequency or severity [26]. Diagnoses
were made according to a standard algorithm alsoNumber of adverse responses given (%)
1 2 3
70.8 9.5 2.4
71.5 11.4 2.0
76.3 4.7 0.4
81.2 3.6 0.4
60.0 20.0 5.0
50.5 24.4 6.8
Table 8 Impact of headache on others assessed by seven questions in three areas of family life
Question
Proportion responding “yes” (%)
Migraine TTH Probable MOH
Relationships, love life and family planning
1. Have your headaches affected your family planning (fewer children, or avoided having children)? 5.5† 1.1† 21.1†
2. During the last 3 months, have your headaches caused difficulties in your love life? 17.8† 5.5† 48.6†
3. Have your headaches caused a relationship to break down (separation or divorce)? 0.7 0.3 7.0
Children
4. During the last 3 months, have your headaches caused one or more of your children to miss school? 1.7† 1.5† 5.0†
5. During the last 3 months, have your headaches prevented you from caring for your children? 18.2† 7.9† 50.0†
Household partner
6. During the last 3 months, have your headaches caused your partner to lose time from work? 2.6† 0.9† 10.7†
7. During the last 3 months, have your headaches caused your partner to miss social activities? 9.1† 2.9† 24.6†
TTH: tension-type headache, MOH: medication-overuse headache.
†Of those to whom the question was applicable (ie, having headache and a household partner and/or children).
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the nature of this study did not allow diagnostic valid-
ation in each of the translations used here, so diagnostic
accuracy was not directly assessed. While it was also a
strength of the study that it enquired simultaneously
into migraine, TTH and MOH, so that these three disor-
ders could be compared with regard to prevalence and
impact, this diagnostic uncertainty must be taken into
account in doing this.
The different sampling methods employed by the
countries produced samples that varied in their repre-
sentativeness of the general population. This was both a
strength, in that it enables comparisons between differ-
ently sourced samples (although that was not a purpose
of the analyses presented here), and a weakness in that
representativeness is an absolute requirement for exter-
nal validity. In fact, there were no obvious differences
between the population- and health-care samples, while
it was readily apparent that headache was more preva-
lent, and had higher impact, in the samples generated
from membership lists of lay groups in Spain, Ireland
and the Netherlands. We expected this, and here ex-
cluded consideration of the lay samples. Among the
population and health-care samples, drawn from nine
countries only, the UK sample showed clear evidence of
biases, with a high proportion having frequent head-
aches, but it was a very small contributor (n = 127) to
the very large total of 8,271 participants. Despite this
large number, the participation rate was low: 27.5% over-
all (excluding Austria and the Netherlands, where it was
unknown), and only 10.6% in Germany and <20% in two
other countries. This means unrecognised biases were
likely. Low participation rates might not be a problem if
the reasons for not responding were unrelated to head-
ache or its impact, but this was probably not so. The
most likely bias was that people affected by headache,and, particularly, people who perceived themselves to be
badly affected, had more interest in responding and were
therefore over-represented. This so-called interest-bias
was detectable in the gender distribution: nearly 60% of
the sample were women, in whom headache is rather
more common.
The non-responder study was conducted to provide
insight into this bias, and it did so. Whereas lifetime head-
ache prevalence was 91% in the main study (in both popu-
lation and health-care samples), in the non-responder
study, with a high participation rate, it was not dissimilar
at 86%. One-year prevalence on the other hand did indi-
cate interest bias: 79.6% (unadjusted) in the main study
versus 64% in non-responders. If a correction were to be
made, we could re-estimate the 1-year prevalence at 68.3%
by taking the weighted average of 79.6% (representative of
the 27.5% of the source population who responded initially
(Table 2)) and 64% (representative of the 72.5% of the
source population who did not). The difference of 11.3%
between this re-estimate and the original suggests that
interest bias may have led to overestimation by some 14%
(relative, calculated as 11.3/79.6*100), which is a moderate
influence. Frequency comparisons between participants in
the main study and initial non-responders provided more
evidence of interest-bias: 41.7% of the former with head-
ache in the last year, but only 24.7% of the latter, reported
headache as a weekly or more frequent occurrence.
While the large sample size meant that measures of
statistical uncertainty (eg, confidence intervals) were
small, clinical uncertainties were therefore far from neg-
ligible. The estimated 1-year prevalence of migraine
(gender-adjusted: 35.3%) is outside the range of other
published studies [2], even recent LTB studies which,
with very careful case-ascertainment, have generally
found migraine to be more prevalent than previously
reported (eg, 20.8% in Russia [10]; 25.6% in India
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overestimation margin of 14% (see above) would reduce
the estimate to 30.4%, which is still high. In fact this
may not be attributable to interest-bias – at least not en-
tirely – since the country with the highest participation
rate (Spain: 58.8%), and therefore least vulnerable to
interest-bias, produced an even higher estimate of
35.4%. A factor is that migraine and probable migraine
were combined, which has been argued to be correct in
epidemiological studies provided that a diagnosis of
probable migraine is trumped (as here) by a diagnosis of
TTH [25,26]. On the other hand, the estimated 1-year
prevalence of TTH (gender-adjusted: 38.2%) is close to
the reported global mean of 42% [2], which does not
suggest any large effect (if any) of questionnaire-
misdiagnosis of TTH as migraine, especially since the
focus on the most bothersome headache in those with
two or more distinct headache types (again a pragmatic
solution [26]) did mean that TTH would not always be
recognized. It might be supposed that the prevalence of
TTH in those with migraine, but not reporting the
former because it was less bothersome, was the same as
in those without, which would inflate the TTH preva-
lence estimate by 13.5% to 43.4%, very close to the re-
ported global mean.
The high prevalence estimates for all headache on ≥15
d/mo (7.2%) and for probable MOH (3.1%) were also, very
probably, influenced by interest-bias. They are not,
however, outside the range of national studies (in Russia,
10.4% and 7.1% respectively were reported [10,26]). These
disorders cause high disability at individual level (discussed
further below); even after discounting to allow for likely
overestimation, these prevalence estimates are indicative
of very substantial population ill-health. They should give
rise to considerable political concern, and remedial action.
Estimates of individual impact, to the extent that they
are dependent on prevalence estimates, may therefore not
be quantitatively exact, but this does not mean they are
not indicative. The general impact gradient (probable
MOH>migraine > TTH) is reassuringly as expected, as
are the gender-related differences. Symptom burden is dif-
ficult to quantify objectively. Duration and intensity of
headache are dimensions of symptom burden, but apt to
be misleading (subject to the effects of any treatments
taken and, in reporting, to recall bias). They are not
reported here, but will be included in another manuscript
focusing on headache on the day prior to the enquiry
(“headache yesterday”), which minimises the effects of
erroneous recall. As to frequency, while >40% of those
with headache reported it as at least a weekly occurrence
(with the non-responder study suggesting this was an
overestimate), this alone, although of interest, is not a good
measure of burden – as is shown by the loose relationship
between frequency and interictal burden (Table 7). As aconsequence of symptom burden, the penalty in lost useful
time is more readily measurable (Tables 5 and 6). Nearly
one fifth of males and over a quarter of females with
migraine reported the loss of >10% of available days, as did
over half of males and nearly two thirds of females with
probable MOH. The inescapable financial implications of
such losses, reported in detail elsewhere [19], again show a
clear gradient at personal level of probable MOH>
migraine > TTH.
Something more should be said about lost time
estimation. It is a well-validated measure of burden [29],
but with a tendency to break down at the very high end.
Our recorded ranges of 0–90 and higher clearly signalled
an element of double counting: neither the workdays
nor the housework days lost in three months can exceed
90 (in fact, few people can claim >65 workdays in 3
months). However, only 2.4% of participants with head-
ache gave responses of ≥45 days to any of the questions
enquiring into lost work, housework or social days, and
over one third of these had probable MOH, so it was
not a significant problem in the sense of being influen-
tial. And it should be assumed that these people, while
not being numerically accurate, were indeed expressing
what they felt was heavy burden. Again, enquiry into
headache yesterday can largely obviate this problem.
The aspects of personal impact identified in Table 4
are worth dwelling on, because they signal effects that
are constant and/or cumulative, not merely present dur-
ing headache episodes. Such consequences are serious
impositions on life, particularly the effects on education,
career and earnings reported by 8-9%. Similar comments
can be made of those aspects of personal impact
reported in Table 8, which in addition affect others than
the people who actually experience headache. Especially
notable are the 18% of parents with migraine and 50%
with probable MOH whose children have not, on at least
one occasion in the preceding 3 months, received the
care they might expect. One in 40 people with migraine
and one in ten with probable MOH have caused their
partners to lose work-time in the last 3 months. These
and many other aspects of interictal burden will be
reported in more detail in a future publication. For many
of them, there is little or no evidence from previous
studies for comparison. The analysis to be done needs to
explain, if it can, why interictal burden assessed by direct
enquiry correlated poorly with headache frequency.
Conclusions
In conclusion, Eurolight should not be seen as a primary
source of prevalence estimates, for which it was neither
intended nor designed. The key findings, while subject
to some diagnostic uncertainty regarding headache type
and to moderate interest-bias, reveal that the common
headache disorders have very high personal impact. The
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headache episodes and beyond the people who actually
experience headache. The level of this impact, and its
pervasiveness, taken together with estimates of huge fi-
nancial cost [19], have important implications for health
policy in Europe, since they are indicators not only of
much public ill-health and unmet health-care need but
also of high but reducible socioeconomic burden.
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